President Trump’s executive order on Monday turned a harsh spotlight on pharmaceutical companies’ long-standing practice of charging Americans far more for prescription drugs than they charge consumers in other countries.
The order’s language remains vague — it mentions only future “price targets” and possible enforcement mechanisms — but the message is unmistakable: The U.S. government will no longer tolerate paying inflated prices for drugs when European governments negotiate far lower ones.